biosimilar drugs

The Obstacles That Impede Biosimilars
The Obstacles That Impede BiosimilarsHurdles to adoption of biosimilars include regulatory issues and lack of interchangeability with the reference drugs.
Will biosimilars deliver on expectations?
Will biosimilars deliver on expectations?This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
What oncologists say about new cancer treatment optionsA new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)
Promising new treatments for plaque psoriasisThe American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.
FDA okays biosimilar for several cancers
FDA okays biosimilar for several cancersWhile FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.
Law Reauthorizes FDA Fees and Increases Access to Generics/BiosimilarsSenate passes FDARA overwhelmingly, ahead of September deadline.
Biosimilars Market Taking Off in the United StatesAfter many years of speculation, a number of biosimilar drugs are hitting the U.S. market.
Biosimilars Have Entered the Market, But Are They Safe?Biosimilars are starting to come on the market, but some have questions about their safety.
Retailers and PBMs Laud Generic/Biosimilar Savings
Retailers and PBMs Laud Generic/Biosimilar SavingsSavings from generic and biosimilar drugs are making PBMs and pharmacies, as well as patients, happy.
Pharmacists: Key Players as Biosimilars Enter the MarketPharmacists will have a central role in educating about biosimilar drugs.